Format

Send to

Choose Destination
See comment in PubMed Commons below
Antiviral Res. 2014 Aug;108:148-55. doi: 10.1016/j.antiviral.2014.06.001. Epub 2014 Jun 16.

Formulation of cidofovir improves the anti-papillomaviral activity of topical treatments in the CRPV/rabbit model.

Author information

  • 1Department of Pathology, Penn State College of Medicine, Hershey, PA 17033, United States; Department of Microbiology and Immunology, Penn State College of Medicine, Hershey, PA 17033, United States. Electronic address: ndc1@psu.edu.
  • 2Department of Pathology, Penn State College of Medicine, Hershey, PA 17033, United States.

Abstract

Current topical treatments for papillomas use ablative, cytotoxic and immunomodulating strategies and reagents. However, the effectiveness of topical treatments using different formulations has not been examined in preclinical models or clinical trials. The purpose of this study was to determine whether formulation of the small molecule acyclic nucleoside, cidofovir (CDV), could lead to improved therapeutic endpoints following topical treatment of papillomas using the cottontail rabbit papillomavirus (CRPV)/rabbit model. Different formulations with a set dose of 1% cidofovir were tested to establish comparative data. The results demonstrated that anti-papilloma treatments with topical CDV were greatly enhanced when formulated versus unformulated. Best results were obtained with CDV formulated in cremophor, then in Carbomer 940, and then in DMSO. Further studies indicated that effective formulations led to complete cures of papillomas at dilutions less than 0.3% CDV. These studies together with previous observations demonstrated that unformulated CDV under the same treatment regime required doses of 2% to achieve cures demonstrating that much less compound can be used when properly formulated.

Copyright © 2014 Elsevier B.V. All rights reserved.

KEYWORDS:

Anti-tumor treatments; Antiviral compound; CRPV/rabbit model; Cidofovir; Formulation; Papillomavirus

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk